InMed Pharmaceuticals Inc (INM)

[Aladdin80]

I agree that for InMed, execution of biosynthesis program will be the only likely near term (<1 yr) catalyst. The broader market doesn't care much about a rare disease (small patient pool) like EB and as much as I'd celebrate finally seeing some IP secured (biosyn, ocular) I don't see it driving the SP very far north.

My prediction is that they'll need more $$ before biosynthesis comes online, if ever. They themselves dropped the honest data point during the biz update about hitting a biological burden during scale-up....in InMed terms that usually means years of addtl research and test. Hoping they can muster something for a nice pump in an effort to capitalize on June warrants and I'll shave my position by 50-60%.